QC parameters for therapeutic pDNA

With the advent of a number of pDNA candidates as COVID vaccine, plasmid DNA (pDNA) production and quality control is going through rapid transition with more and more process development and QC parameters. I have tried jotting down all the QC parameters that can help any therapeutic pDNA candidate pass through regulatory authorities. Here they are:

Moreover, it has been seen that residual presence of beta lactams is very much unwanted, so Kanamycin resistance is generally preferred in the pDNA backbone.

Do save it for future references, share if you think it can help others. Cheers!